Literature DB >> 30007088

Donor cell-derived acute promyelocytic leukemia after allogeneic hematopoietic stem cell transplantation.

Anne Bouvier1,2,3, Bénédicte Ribourtout1,2, Sylvie François2,4, Corentin Orvain2,3,4,5, Damien Luque Paz1,2,3,5, Annaëlle Beucher1,2, Alexandre Guérard1,2,5, Philippe Guardiola2,3,4,5,6, Valérie Ugo1,2,3,5, Odile Blanchet1,2,3,5,7, Franck Geneviève1,2, Aline Schmidt2,3,4,5, Mathilde Hunault-Berger2,3,4,5.   

Abstract

Donor cell leukemia (DCL) is an infrequent complication after allogeneic hematopoietic stem cell transplantation (HSCT). Its true incidence is difficult to assess, although improvements in chimerism studies contributed to a better diagnosis of DCL. We report two rare cases of donor cell-derived acute promyelocytic leukemia (APL). To our knowledge, only two cases have been described in the literature. Here, we report one male and one female patients with acute myeloid leukemia (AML), who developed an APL in donor cells after HSCT. The latency between HSCT and DCL was 279 and 43 months, respectively. Fluorescent in situ hybridation and chimerism monitoring analysis proved the donor origin of APL. Surprisingly, donor lymphocyte infusion provided a hematological response during 19 months in the female patient. The mechanisms associated with pathogenesis of DCL are unclear and seem to be multifactorial. Increasing worldwide allogeneic hematopoietic stem cell transplantation activity and potentially the age of donor could explain the increasing incidence of DCL in the future. It is highlighted that long-term follow up of recipients will allow to report all cases of DCL, to clarify the genetic landscape and factors which contribute to DCL, to understand the response to DLI.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  acute myeloid leukemia; bone marrow transplantation

Mesh:

Substances:

Year:  2018        PMID: 30007088     DOI: 10.1111/ejh.13143

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  6 in total

1.  Quantitative chimerism in CD3-negative mononuclear cells predicts prognosis in acute myeloid leukemia patients after hematopoietic stem cell transplantation.

Authors:  Anne Bouvier; Jérémie Riou; Sylvain Thépot; Aurélien Sutra Del Galy; Sylvie François; Aline Schmidt; Corentin Orvain; Marie-Hélène Estienne; Alban Villate; Damien Luque Paz; Laurane Cottin; Bénédicte Ribourtout; Annaëlle Beucher; Yves Delneste; Norbert Ifrah; Valérie Ugo; Mathilde Hunault-Berger; Odile Blanchet
Journal:  Leukemia       Date:  2019-11-25       Impact factor: 11.528

Review 2.  Genetics of donor cell leukemia in acute myelogenous leukemia and myelodysplastic syndrome.

Authors:  Lacey Williams; Kimberley Doucette; Judith E Karp; Catherine Lai
Journal:  Bone Marrow Transplant       Date:  2021-03-08       Impact factor: 5.483

3.  Lessons Learned from Donor Cell-Derived Myeloid Neoplasms: Report of Three Cases and Review of the Literature.

Authors:  Komal Galani Deshmukh; Katalin Kelemen
Journal:  Life (Basel)       Date:  2022-04-08

4.  Establishment and characterization of HXWMF-1: the first mouse fibroblastic tumor cell line derived from leukemia-associated fibroblasts.

Authors:  Yuanyuan Li; Ling Gu
Journal:  Cancer Cell Int       Date:  2021-03-19       Impact factor: 5.722

5.  Assessment of Minimal Residual Disease by Next Generation Sequencing in Peripheral Blood as a Complementary Tool for Personalized Transplant Monitoring in Myeloid Neoplasms.

Authors:  Paula Aguirre-Ruiz; Beñat Ariceta; María Cruz Viguria; María Teresa Zudaire; Zuriñe Blasco-Iturri; Patricia Arnedo; Almudena Aguilera-Diaz; Axier Jauregui; Amagoia Mañú; Felipe Prosper; María Carmen Mateos; Marta Fernández-Mercado; María José Larráyoz; Margarita Redondo; María José Calasanz; Iria Vázquez; Eva Bandrés
Journal:  J Clin Med       Date:  2020-11-25       Impact factor: 4.241

6.  Simultaneous Monitoring of Mutation and Chimerism Using Next-Generation Sequencing in Myelodysplastic Syndrome.

Authors:  Jong-Mi Lee; Yoo-Jin Kim; Sung-Soo Park; Eunhee Han; Myungshin Kim; Yonggoo Kim
Journal:  J Clin Med       Date:  2019-11-28       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.